| Known as |
UV-4 |
ClinicalTrials.gov intervention name — accepted as the source's own label NCT02061358 ↗
|
| Known as |
MON-DNJ |
“BACKGROUND: UV-4 (N-(9'-methoxynonyl)-1-deoxynojirimycin, also called MON-DNJ) is an iminosugar small-molecule oral drug candidate” PMID 35939501 ↗ Aug 2022
|
| Known as |
N-(9'-methoxynonyl)-1-deoxynojirimycin |
“BACKGROUND: UV-4 (N-(9'-methoxynonyl)-1-deoxynojirimycin, also called MON-DNJ) is an iminosugar small-molecule oral drug candidate” PMID 35939501 ↗ Aug 2022
|
| Known as |
UV-4 hydrochloride |
“Randomized single oral dose phase 1 study of safety, tolerability, and pharmacokinetics of Iminosugar UV-4 Hydrochloride (UV-4B) in healthy subjects.” PMID 35939501 ↗ Aug 2022
|
| Known as |
UV-4B |
“Randomized single oral dose phase 1 study of safety, tolerability, and pharmacokinetics of Iminosugar UV-4 Hydrochloride (UV-4B) in healthy subjects.” PMID 35939501 ↗ Aug 2022
|
| Action |
Inhibit |
“The antiviral mechanism of action of UV-4 is through inhibition of the host endoplasmic reticulum-resident α-glucosidase 1 and α-glucosidase 2 enzymes.” PMID 35939501 ↗ Aug 2022
|
| Modality |
Small molecule |
“is an iminosugar small-molecule oral drug candidate” PMID 35939501 ↗ Aug 2022
|